91 results about "Neoplasm diagnosis" patented technology

The present invention relates to a method and system for predicting the probability of normal tissue damage based on deep learning, belonging to the technical field of medical data processing. The method includes: obtaining the tumor dose data, basic information, and tumor diagnosis information of a patient; the tumor dose data is formulated by a doctor based on the patient's tumor diagnosis information before radiotherapy for the patient; the basic information includes at least the patient's age; based on the tumor dose data, obtaining the dose volume histogram of the patient; based on the dose volume histogram, obtaining the volume parameters and biological equivalent dose of the patient's normal tissue; inputting the volume parameters and biological equivalent dose of the patient's normal tissue, the patient's basic information, and tumor diagnosis information into a normal tissue damage probability prediction model constructed based on deep learning to obtain the damage probability of the patient's normal tissue. Compared with traditional statistical models or empirical formulas, the prediction accuracy of this method is higher, and it can more accurately evaluate the damage probability of normal tissue.

The invention provides a preparation method and application of a CD70 specific nano antibody molecular imaging probe. The probe comprises a tumor targeting group, radionuclide and a bifunctional chelating agent, the tumor targeting group is a CD70 specific nano antibody; the CD70 specific nano antibody is R8B4, and the amino acid sequence of the R8B4 is as shown in SEQ ID No. 1. The probe provided by the invention can realize noninvasive diagnosis of solid tumors such as renal clear cell carcinoma and malignant tumors of a blood system; reabsorption of the compound in the kidney is effectively inhibited through charge adjustment, kidney uptake is remarkably reduced, non-specific signals are reduced, the signal-to-noise ratio during targeted imaging or treatment is increased, and the imaging quality and treatment safety are improved. The probe not only has a wide application prospect in tumor diagnosis, but also provides a new technical support for targeted therapy and individualized precision medical treatment, and has important scientific research and clinical application values.

The invention discloses a tumor targeting reagent and application thereof in tumor diagnosis. The targeting reagent has strong affinity to tumors, strong specificity and no biotoxicity, is relatively stable in vivo, and can be used as a molecular probe to be applied to molecular imaging and / or treatment of various integrin alpha6 high-expression tumors; the targeting reagent provided by the invention comprises the tumor targeting peptide RWYDeA, and further comprises a radionuclide chelating agent, other connecting structures and a hydroxyl substitution structure, and the structure is beneficial to improving the tumor targeting property of the targeting reagent, prolonging the tumor binding time and achieving a better tumor diagnosis effect; the method can be used for preparing products for diagnosing / treating diseases related to high expression of integrin alpha6.

The application discloses an exosome small non-coding RNA molecule marker and application thereof, and belongs to the field of tumor liquid biopsy and molecular diagnosis. The exosome small non-coding RNA molecule marker is at least one of tRNA-GlyGCC-5 and sRESE; the nucleotide sequence of the tRNA-GlyGCC-5 is shown as SEQ ID NO:1; and the nucleotide sequence of the sRESE is shown as SEQ ID NO:2. The sRESE in the application is a brand new small non-coding RNA sequence, and is first discovered by the inventor, which is important for the marker of esophageal cancer and the research on disease progression mechanism. The tumor diagnosis kit provided by the application, which comprises the exosome small non-coding RNA molecule marker, is a liquid diagnosis monitoring kit with non-invasiveness, high sensitivity, high specificity and applicability to general survey or screening.

The invention belongs to the field of computational biology calculation, and particularly relates to a colorectal cancer metabolism information generality analysis method based on intrinsic learning. The method comprises the following steps: firstly, training a deep learning model, and identifying an intrinsic metabolite of the colorectal cancer from a high-resolution tumor space metabonomics data set of the colorectal cancer; secondly, introducing a distribution selection mechanism and an intrinsic learning method, and efficiently screening intrinsic metabolites highly related to colorectal cancer diagnosis and staging; then, inputting the intrinsic metabolites into the tumor prediction network to estimate the tumor condition; and finally, evaluating the effectiveness of the screened intrinsic metabolites through multi-task verification, including tumor diagnosis and T / N / M staging prediction of colorectal cancer. Experimental results show that the colorectal cancer screened based on the model is predicted, the AUC in tumor diagnosis and T / N / M staging prediction tasks exceeds 0.9, and the model has high clinical application value.

According to the exosome multi-target detection method based on the nano-frame multi-satellite mode, a high-stability tetrahedron is used as a core skeleton, multiple high-protein-affinity nucleic acid aptamer tongs are assembled and matched according to needs to construct a high-reproducibility biomarker recognition element, a molecular form with multiple satellites wrapping exosome is constructed, and the exosome multi-target detection method based on the nano-frame multi-satellite mode is obtained. According to the method, a'free satellite 'element is formed, and flow cytometry is utilized to detect the particle size and output signals with ultralow background interference, so that multiple detection requirements of different tumors on different expression levels of different markers in different development processes can be met, and an identification-separation-detection integrated high-specificity exosome detection strategy is realized. Clinical examination and diagnosis requirements serve as fundamental guidance, detection potential is excavated on an existing basic flow platform, instrument detection particle size limitation is turned into background killer, a new instrument detection thought is widened, detection performance is improved, exosome encrypted information decoding is accelerated, and the transformation progress of clinical disease prevention and treatment and tumor diagnosis and treatment is promoted and guided.

The invention discloses an intelligent tumor diagnosis large model construction method based on multi-modal medical data fusion. The method comprises the steps of 1, data collection processing and feature extraction, 2, establishment of a dynamic fusion model, 3, arrangement of a training set, 4, model training optimization, 5, establishment of an auxiliary diagnosis model and 6, model deployment. According to the method, a three-level fusion mechanism of a self-adaptive fusion framework is established, medical image data and clinical data of various modes are effectively fused, the model is trained by using a double-domain transfer learning strategy, the small sample learning efficiency and precision are improved, the characteristics of tumors can be reflected more comprehensively and accurately, and the method is suitable for large-scale popularization and application. A powerful auxiliary reference is provided for improving the accuracy and efficiency of tumor diagnosis, and the model can be expanded and deployed in other disease auxiliary diagnosis reference systems and has a wide application prospect.

The invention discloses an ultrasonic tumor examination system for the obstetrics and gynecology department. The ultrasonic tumor examination system comprises a data acquisition module, a data processing module, a data analysis module and a result output module. The data acquisition module synchronously acquires pressure distribution, tumor morphological characteristics and blood flow data; the data processing module maps the pressure field to an ultrasonic image to generate a superposition graph, so that a three-dimensional space model is constructed, and deformation caused by breathing or vascular pulsation is corrected; the data analysis module divides regions according to tumor boundaries determined by pressure, calculates hemodynamic and morphological parameters of each region, and outputs malignancy probability classification through a convolutional neural network; and the result output module generates a space-function thermodynamic diagram and a diagnosis report, and also can form a four-dimensional dynamic report in combination with historical data, thereby improving the tumor diagnosis accuracy, realizing accurate matching of multi-dimensional information, and providing a more comprehensive basis for tumor property judgment.

The invention belongs to the technical field of cell sampling and inspection, and particularly relates to an inspection device for oncology department, which comprises a puncture cylinder composed of an upper needle tube and a lower needle tube; the protection assembly is arranged in the puncture cylinder; the trigger assembly is arranged at the upper end of the protection assembly and used for activating a protection mechanism of the protection assembly; the linkage assembly is arranged at the lower end of the lower needle tube; wherein the protection assembly comprises a supporting part, the supporting part is connected into the lower needle tube in a sliding mode, the upper end of the supporting part is connected with a pressing block in a sliding mode, and a capsule is arranged between the supporting part and the pressing block. By introducing a dynamic protection mechanism, a built-in instant freezing system and a modular structural design, the defects of an existing puncture sampling device in the aspects of safety, sample storage, structural flexibility and the like are overcome, and the device has remarkable technical progress and practical value and is suitable for being widely applied to the field of tumor diagnosis.

The invention relates to the technical field of biological medicine and tumor diagnosis, and particularly discloses a human epididymal protein 4 tumor marker and application thereof. The high expression of the human epididymal protein 4 tumor marker gene is closely related to the prognosis of an ovarian cancer patient, and the human epididymal protein 4 can be used as an ovarian cancer tumor marker and has important significance on the diagnosis, treatment and prognosis evaluation of ovarian cancer; the invention provides a detection primer pair of a human epididymal protein 4 tumor marker and application of the detection primer pair as an ovarian cancer diagnosis kit, ovarian cancer diagnosis can be more accurate and rapid, the early diagnosis level of ovarian cancer is improved, and the invention further provides a human epididymal protein 4 tumor marker expression inhibitor siRNA which can be used for detecting the human epididymal protein 4 tumor marker. When being used for inhibiting the expression of the human epididymal protein 4 tumor marker, the human epididymal protein 4 tumor marker has a good interference effect and has clinical application potential.

The invention provides an acoustic-magnetic dual-mode diagnosis and treatment agent as well as a preparation method and application thereof, and belongs to the technical field of preparation of tumor diagnosis and treatment agents. The acoustic-magnetic dual-mode diagnosis and treatment agent is surface-modified magnetic nanoparticles which contain nano balloon genes and are subjected to Escherichia coli induced expression; the nucleotide sequence of the nano-balloon gene is a sequence shown as NCBI: KC601845.1, escherichia coli in the acoustic-magnetic dual-mode diagnosis and treatment agent as a diagnosis and treatment agent carrier has an active targeting property on a tumor hypoxic region, and bacteria contain a nano-balloon and have an acoustic response characteristic; the escherichia coli surface modified magnetic nanoparticles have a magnetic response characteristic. In acoustic-magnetic dual-mode imaging, firstly, on a real-time ultrasonic contrast monitoring image, a nano air bag expressed in bacteria can generate an enhanced tumor ultrasonic echo signal; secondly, under the action of an external changing magnetic field, the magnetic nanoparticles on the surfaces of the bacteria can generate an enhanced tumor magnetic vibration imaging effect, so that more efficient tumor diagnosis and / or treatment can be realized.

The present application relates to the field of tumor markers, in particular to a fascin acetylation modification which can be used as a tumor diagnosis and prognosis analysis marker, a detection reagent and application thereof. The present application is directed to the fact that acetylation modification at K41 site of fascin significantly inhibits the cancer-promoting activity of fascin protein, and in esophageal cancer tissue, the proportion of fascin with acetylation modification at K41 site is significantly lower than that of wild-type fascin in para-cancerous tissue. Based on the acetylation at K41 site of fascin, a specific antibody for acetylation at K41 site of fascin is developed, so as to conduct clinical application research on acetylation at K41 site of fascin, and establish an esophageal cancer prognosis analysis model and targeted treatment.

The invention relates to a mutant calreticulin for diagnosis of myeloid malignant tumors. A method for diagnosing myeloid malignancies comprising determining the presence of a mutant allele of a calreticulin gene is disclosed. In addition, genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are also subject matter of the invention. Furthermore, the invention relates to the medical use of inhibitors of the mutant calreticulin.

Provided is use of an endogenous micropeptide in cancer diagnosis or treatment. Particularly, the present invention relates to use of a micropeptide encoded on a long non-coding RNA as a tumor marker, a tumor treatment drug, and / or a tumor treatment target. Specifically, two micropeptides and variants thereof have been discovered for the first time. Moreover, provided are nucleotide sequences encoding the described micropeptides and recombinant vectors containing these nucleotide sequences, and also provided are use thereof in the preparation of a reagent or a drug for diagnosing, preventing, alleviating, or treating a tumor, and use of a drug or a reagent for an interfering micropeptide or a coding nucleic acid thereof in the preparation of a medicament or a pharmaceutical composition for preventing, alleviating, or treating a disease. The micropeptides not only provide biomarkers for the diagnosis of tumors, but also provide therapeutic drugs or therapeutic targets for the treatment of tumors.

The present disclosure discloses a brand-new skeleton 99mTc-FAPI diagnostic probe and use thereof in the preparation of a drug or a reagent for diagnosing tumors, wherein the structural formula of a dimeric compound targeting FAP is shown by following formula. Compared with conventional FAP inhibitor radiopharmaceuticals, technetium-99m-labeled novel skeleton FAP inhibitor dimeric compound has a very high tumor uptake rate, high contrast between tumor and background and good in vivo biodistribution.

A multimodal hyperspectral vibrational sum-frequency generation (VSFG) platform and a method of tumor diagnosis are provided. The method employs the chemical-specific VSFG microscopy platform as a label-free imaging technique for tumor identification.

The application discloses a cervical cancer circRNA marker and application thereof, and belongs to the technical field of biology. The inventors have found that the expression level of circular RNA hsa_circ_0002828 in the plasma of a cervical cancer patient is significantly lower than that in the plasma of a healthy person, thereby indicating that hsa_circ_0002828 can be used as a diagnostic marker for cervical cancer and for predicting the occurrence of cervical cancer. Meanwhile, after overexpression of hsa_circ_0002828, the proliferation ability and invasion ability of cervical cancer cells can be significantly inhibited, and tumor cell apoptosis can be strongly induced. These results show that hsa_circ_0002828 can be used as a tumor diagnosis marker and a potential target for tumor treatment, and is expected to be applied to the diagnosis and treatment of cervical cancer.

The invention discloses an application of circular RNA (Ribonucleic Acid) in tumor diagnosis and / or treatment. According to the present invention, high-throughput sequencing is adopted to detect the disordered expression circRNA in the metastasis cells, then a stable lung cancer cell model for overexpressing and knocking down the target circRNA is constructed, CCK-8 and transwell migration, invasion and other experiments are performed, and the cyclic structure of the circDCP2 and the up-regulation expression of the circDCP2 in the lung cancer cells are confirmed and verified, the result shows that knock-down of the circ DCP2 has a remarkable inhibition effect on the vicious transformation of BEAS-2B cells induced by the CBNPs. The circDCP2 can be used as a reliable biomarker for early lung cancer diagnosis and disease treatment.

The invention discloses a novel nuclear magnetic resonance contrast agent Gd-DOTA-PP for targeting citrullinated histone to achieve neutrophil extracellular trap net imaging and a preparation method and application thereof.The method comprises the steps that citrullinated histone targeting polypeptide PP and ligand molecules DOTA-NHS are combined, and a compound DOTA-PP is obtained; and then gadolinium (Gd) ions are introduced into the DOTA-PP through a coordination reaction, and the novel contrast agent Gd-DOTA-PP is prepared. The contrast agent can be selectively combined with an important marker, namely citrullinated histone, of neutrophil extracellular trapping nets (NETs), and T1 weighted imaging signals of a target area are remarkably enhanced. The preparation method is simple and convenient to operate, the preparation process is highly controllable, and the obtained contrast agent has excellent biocompatibility and targeting characteristic. The accurate targeting ability of the probe enables the influence signal of the probe in NETs enrichment areas such as tumor early metastasis, tumor infiltration lymph nodes and the like to be obviously enhanced, a powerful tool is provided for tumor diagnosis, especially accurate diagnosis of the early metastasis, and the probe has important clinical application value.

The application provides a boundary-aware three-dimensional MRI tumor segmentation method and a tumor diagnosis device. The method comprises: acquiring three-dimensional MRIs of multiple tumor patients as a tumor dataset, the three-dimensional MRIs comprising gadolinium-enhanced T1 SC slices; performing tumor segmentation on the three-dimensional MRIs in the tumor dataset as input of a first segmentation model to obtain a class label of the tumor in the three-dimensional MRI; wherein the first segmentation model is a model based on a convolutional neural network (CNN), the first segmentation model comprises a first model branch and a second model branch, the first model branch is used for predicting the class label, and the second model branch is used for predicting a surface distance field of the tumor based on boundary awareness, the surface distance field is used for describing the nearest distance of each voxel in the three-dimensional MRI to the surface of the tumor, and the training and optimization of the first segmentation model are based on the training and optimization of the first model branch and the second model branch.

The invention provides a tumor identification method based on multi-modal information cooperation, and relates to the technical field of tumor identification. The method comprises the following steps: firstly, constructing a multi-modal cooperative characterization unit, synchronously receiving medical image and electrical impedance time sequence data, cooperatively mining macroscopic morphological association features and microscopic difference features of a tumor by using a multi-domain coupling characterization space technology, and outputting a multi-modal cooperative feature vector; then, an electrical impedance time sequence analysis unit is built, electrical impedance signal deep correlation features are extracted through time sequence feature multi-order analysis, and electrical impedance deep feature vectors are output; then designing a dynamic feature adaptation fusion unit, performing adaptive fusion and dimension recombination on the multi-modal collaborative feature vector and the electrical impedance deep feature vector based on a feature responsivity adaptation technology, and outputting a stabilized fusion feature vector; and finally, constructing a feature correlation judgment engine, quantifying the feature contribution degree based on a structural causal model and a multi-layer correlation verification technology, and outputting a tumor diagnosis result. The problems of insufficient multi-modal feature collaboration and explanatory deviation caused by black box mapping in the prior art are effectively solved, and the accuracy and logic robustness of tumor recognition are improved.

There is described herein a method of prognosing or classifying a subject with a Myeloproliferative Neoplasm (MPN) comprising: (a) determining the expression level of at least 10 genes in a test sample from the subject selected from the group consisting of SPP1, CEACAM6, GJA1, IGSF10, IGFBP2, COL4A5, LYVE1, MTIE, EMP1, XIST, DLK1, TPSAB1, TIMP3, CLC, MS4A1, ENKUR, ALOX12, KNDC1, HLA-DQB1, GAS2, CLEC2L, BEND2, CDH7, and NT5E; and (b) comparing expression of the at least 10 genes in the test sample with reference expression levels of the at least 10 genes from control samples from a reference cohort of patients; wherein a difference or similarity in the expression of the at least 10 genes in the test sample and the reference expression levels is used to prognose or classify the subject with MPN into a low risk group or a high risk group for worse survival.

The present application relates to the field of clinical laboratory medicine technology, in particular to a neuroblastoma and catecholamine-related tumor diagnosis kit and its application. The kit contains key components for detecting high vanillylmandelic acid and vanillylmandelic acid in urine, including isotope internal standard, specific chromatographic column, optimized mobile phase and sample pretreatment material. The detection method using the kit optimizes the collection, preservation and pretreatment process of instant urine samples, and combines the liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis conditions designed for low concentration and complex matrix samples to realize the rapid and accurate quantification of trace HVA and VMA in urine. It overcomes the shortcomings of traditional 24-hour urine detection method such as large trauma, long cycle and poor accuracy, and provides an efficient and reliable solution for non-invasive, early diagnosis and postoperative efficacy monitoring of neuroblastoma and other catecholamine-related tumors, which has important clinical application value.

The invention relates to a gold nano radiotherapy sensitizer for surface enhanced Raman spectroscopy and a preparation method and application thereof. Specifically, the invention provides a composite material with manganese dioxide wrapped by gold nanoparticles, which has improved surface enhanced Raman spectrum signals, improved X-ray deposition efficiency and improved tumor killing effect in radiotherapy. And a nucleic acid aptamer for targeting tumors can be carried, so that the targeting property and the safety are improved, and wide application prospects are realized in the fields of radiotherapy sensitization, tumor diagnosis and the like. In addition, the invention further provides a method for preparing the gold nano composite material, dopamine-grafted polyethylene glycol, gold nano particles, potassium permanganate and the like in different proportions are used as raw materials, and the gold nano composite materials with different shapes and sizes can be prepared and used for different purposes. The preparation method is simple, easy to operate and beneficial to industrial production and application.

The invention discloses a machine learning-based tumor early screening expiration VOCs marker identification and verification method. The method comprises the steps of obtaining and processing high-dimensional full-spectrum expiration VOCs data; a generalized linear model is adopted to evaluate the influence of the queue correlation difference on the expiratory VOCs data, and VOCs with significant interaction are removed; screening potential expired VOCs biomarkers with significant difference between an experimental group and a control group by adopting a difference volcano plot method in which a kernel weighting function is introduced; a Boruta feature screening algorithm based on a random forest is adopted, and an expiration VOCs biomarker panel most related to the tumor is constructed; and evaluating the tumor diagnosis and grading performance of the expired VOCs biomarker panel by adopting a machine learning algorithm based on multiple underlying logics. According to the method, a marker panel construction process based on a machine learning algorithm is created, and a biomarker panel suitable for various algorithms is accurately and efficiently captured from massive expired VOCs.

The present invention relates to a boron carrying agent for integrated tumor diagnosis and treatment, and a preparation method therefor and use thereof. Provided is a compound represented by formula I: wherein an R group is hydrogen or alkyl. A boron atom connected to the benzene ring may be 10B or natural boron, and at least one fluorine atom in -BF 3 - is radiolabeled. The present invention generally relates to the fields of radiopharmaceuticals and nuclear medicine. The compound in the present invention can be used for a drug for integrated diagnosis and treatment in tumor diagnosis and BNCT treatment, and by means of the same chemical structure, a reliable distribution result of a drug in vivo is provided.

The present application relates to the technical field of squamous cell carcinoma early diagnosis, and provides a method for assisting early diagnosis of head and neck squamous cell carcinoma, comprising: S1: collecting existing video data obtained by using MET targeted near-infrared fluorescence imaging technology, and training a supervised learning model by using the video data set; S2: building a classifier system, inputting video data to be classified into the classifier system, and applying the trained supervised learning model to segment and determine the pathological properties of the lesion; S3: comparing the efficiency of the built classifier system and human doctors in diagnosing early head and neck squamous cell carcinoma; S4: screening key features related to the occurrence and development of head and neck squamous cell carcinoma through the classifier system, forming a comprehensive data set by connecting the key features with multi-omics data, building an intermediate model based on the comprehensive data set, and performing bioinformatics analysis by using the intermediate model. The present application can improve the early detection rate of HNSCC, improve the accuracy of biopsy, and realize early and accurate tumor diagnosis.

The present invention provides a CD70-specific nanoantibody, a molecular imaging probe, and a preparation method and application thereof. The probe includes a tumor-targeting group, a radionuclide, and a bifunctional chelator; the tumor-targeting group is a CD70-specific nanoantibody; the CD70-specific nanoantibody is RD06, and the amino acid sequence of RD06 is shown in SEQ ID No. 1. The probe of the present invention can achieve non-invasive diagnosis of solid tumors such as renal clear cell carcinoma and hematological malignancies; and through charge adjustment, it effectively inhibits its reabsorption in the kidney, significantly reduces renal uptake, reduces nonspecific signals, improves the signal-to-noise ratio during targeted imaging or treatment, and improves imaging quality and treatment safety. This probe not only has broad application prospects in tumor diagnosis, but also provides new technical support for targeted therapy and personalized precision medicine, and has important scientific research and clinical application value.

An engineered cell membrane nanovesicle and a preparation method therefor and use thereof. A use of normal fibroblasts in the preparation of a drug or tumor diagnostic reagent or nano-drug delivery system or engineered vesicle for treating tumors. The vesicle prepared using the normal fibroblasts has high specificity and the ability to quickly target various types of tumor tissues, and can achieve tumor targeted diagnostic imaging or drug delivery; also, the accumulation in normal organs and non-targeted tissues is greatly reduced, the toxic side effects in vivo are minimized, and safety and effectiveness are greatly improved.

The application discloses a methoxynaphthalene fluorescent compound and application thereof. The fluorescent compound can be used as a fluorescent probe and can detect pH value changes in a solution and cells. Compared with a probe for qualitatively researching the strength of pH value, the probe can quantize the pH value of the solution and can research the pH value changes in the cells. Therefore, the fluorescent compound can be used for preparing a pH value sensitive tumor diagnosis reagent, a fluorescent imaging reagent or a radioactive imaging reagent of the tumor.